Trials / Terminated
TerminatedNCT05466240
Study of AT-752 in Patients With Dengue Infection
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of AT-752 in Patients With Dengue Infection
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Atea Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The Phase 2 study will be conducted in adult patients with confirmed Dengue infection and will investigate safety, PK, and pharmacodynamics (PD) in this population. The study will be conducted in several dosing cohorts to enable dose selection for subsequent trials
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT-752 | AT-752 for 5 days |
| DRUG | Placebo | Placebo for 5 days |
Timeline
- Start date
- 2022-04-29
- Primary completion
- 2023-01-19
- Completion
- 2023-01-19
- First posted
- 2022-07-20
- Last updated
- 2024-03-05
- Results posted
- 2024-03-05
Locations
32 sites across 10 countries: Brazil, Colombia, Ecuador, India, Malaysia, Peru, Philippines, Taiwan, Thailand, Vietnam
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05466240. Inclusion in this directory is not an endorsement.